SecBot SecBot
8-K ·Filed Nov 4, 2026

CYTK

CYTOKINETICS INC
BULLISH
Impact 6/10
Horizonweeks Processed12d 7h ago SEC0001193125-26-447198
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The rapid MYQORZO revenue ramp and beat on both top and bottom lines confirm strong commercial execution. The upcoming sNDA filing for nHCM in Q4 2026 is the next major catalyst; monitor FDA acceptance and PDUFA timeline.

DirectionBullish
Confidencehigh
Horizonweeks

MYQORZO

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Next catalyst
None dated

What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

Price Chart

Loading chart...

Executive Summary

Cytokinetics reported Q3 2026 MYQORZO net product revenue of $44.5M, up sharply from $4.8M in Q1 2026, and total revenue of $47.6M, beating the $42.3M consensus. The net loss of $190.1M ($1.37 per share) narrowed from $306.2M ($2.55 per share) a year ago and beat the $-1.41 EPS consensus. The company reaffirmed its 2026 guidance and plans to file a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.

Key Financial Metrics

EPS
−$1.37
est −$1.41 · +2.8%
Revenue
$47.6M
est $42.3M · +12.4% · +2357.0% YoY
Rating
beat

Key Facts

  • MYQORZO net product revenue of $44.5M in Q3 2026, up from $4.8M in Q1 2026
  • Total revenue of $47.6M beat consensus of $42.3M
  • Net loss of $190.1M ($1.37 per share) beat consensus EPS of $-1.41 and narrowed from $306.2M loss a year ago
  • Cash, cash equivalents and investments of ~$1.6B as of September 30, 2026
  • Company reaffirmed full year 2026 GAAP combined R&D and SG&A expense guidance of $860M-$890M
  • Plans to submit supplemental NDA for aficamten in non-obstructive HCM in Q4 2026 and Type II Variation in EU in early 2027
  • Nearly 1,100 unique HCPs prescribed MYQORZO YTD; over 2,800 patients dispensed
  • MYQORZO received marketing authorization in Canada and the UK during Q3

Financial Impact

Q3 MYQORZO net product revenue of $44.5M; total revenue $47.6M vs consensus $42.3M; net loss $190.1M vs consensus loss $195.5M (implied)

revenueepscash

Risk Factors

  • Company remains unprofitable with significant operating losses and cash burn
  • Heavy debt load and revenue participation obligations (Royalty Pharma) create financial leverage
  • Regulatory and commercial risk for nHCM expansion; competition from other cardiac myosin inhibitors

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-447198
Document: cytk-20261104.htm0001193125-26-447198
Document: 0001193125-26-447198-index-headers.html0001193125-26-447198
Document: 0001193125-26-447198-index.html0001193125-26-447198
Document: 0001193125-26-447198.txt0001193125-26-447198
8-K Data (Synthetic)0001193125-26-447198

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 Viewing No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (9h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026